Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis

被引：0

作者：

Siegfried, Elaine ^{[1
]}

Cork, Michael ^{[2
]}

Boguniewicz, Mark ^{[3
]}

Deleuran, Mette ^{[4
]}

Simpson, Eric ^{[5
]}

Chen, Zhen ^{[6
]}

Clearfield, Drew ^{[6
]}

Shah, Parul ^{[7
]}

Rodriguez-Marco, Ainara ^{[8
]}

机构：

[1] St Louis Univ, St Louis, MO USA

[2] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England

[3] Natl Jewish Hlth, Denver, CO USA

[4] Aarhus Univ Hosp, Aarhus, Denmark

[5] Oregon Hlth & Sci Univ, Portland, OR USA

[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[7] Regeneron, Tarrytown, NY USA

[8] Sanofi, Paris, France

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2023年 / 151卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

456

引用

页码：AB149 / AB149

页数：1

共 50 条

[1] Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis
Siegfried, Elaine C.
Cork, Michael J.
Boguniewicz, Mark
Deleuran, Mette
Simpson, Eric L.
Chen, Zhen
Clearfield, Drew
Shah, Parul
Rodriguez Marco, Ainara
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[2] Dupilumab Reduces Inflammatory Biomarkers in Patients Aged 6 Months to 18 Years With Moderate-to-Severe or Severe Atopic Dermatitis
Beck, Lisa
Muraro, Antonella
Boguniewicz, Mark
Chen, Zhen
Levit, Noah
Marco, Ainara Rodriguez
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB152 - AB152
[3] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
Kraft, Magdalena
Worm, Margitta
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
[4] Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
Silverberg, Jonathan, I
Rubini, Norma P. M.
Pires, Mario C.
Rossi, Ana B.
Zhang, Annie
Chen, Zhen
Levit, Noah A.
Chao, Jingdong
Shumel, Brad
Bego-Le Bagousse, Gaelle
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (05): : 1279 - +
[5] Long-term dupilumab treatment for 100 weeks reduces serum TARC and total IgE in patients with moderate-to-severe atopic dermatitis
Beck, L. A.
Thaci, D.
Bissonnette, R.
Deleuran, M.
Harel, S.
Chen, Z.
Shumel, B.
Rossi, A. B.
ALLERGY, 2020, 75 : 27 - 28
[6] DUPILUMAB REDUCES ITCH IN CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AGED 6 MONTHS TO 5 YEARS
Paller, A. S.
Siegfried, E. C.
Yosipovitch, G.
Kwatra, S. G.
Praestgaard, A.
Prescilla, R.
Wang, J.
VALUE IN HEALTH, 2023, 26 (06) : S57 - S58
[7] Dupilumab Reduces Itch in Children with Moderate-to-Severe Atopic Dermatitis Aged 6 Months to 5 Years
Paller, Amy S.
Siegfried, Elaine C.
Yosipovitch, Gil
Kwatra, Shawn G.
Praestgaard, Amy
Wang, Zhixiao
Prescilla, Randy
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB151 - AB151
[8] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, Lisa A.
Thaci, Diamant
Hamilton, Jennifer D.
Graham, Neil M.
Bieber, Thomas
Rocklin, Ross
Ming, Jeffrey E.
Ren, Haobo
Kao, Richard
Simpson, Eric
Ardeleanu, Marius
Weinstein, Steven P.
Pirozzi, Gianluca
Guttman-Yassky, Emma
Suarez-Farinas, Mayte
Hager, Melissa D.
Stahl, Neil
Yancopoulos, George D.
Radin, Allen R.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 130 - 139
[9] Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis
Beck, Lisa A.
Muraro, Antonella
Boguniewicz, Mark
Chen, Zhen
Zahn, Joseph
Marco, Ainara Rodriguez
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (01)
[10] Treatment satisfaction in patients receiving dupilumab for moderate-to-severe atopic dermatitis
Lans, A.
Van der Schaft, J.
Bakker, D.
Ariens, L.
Thijs, J. H.
De Bruin-Weller, M. S.
Balak, D. M. W.
ALLERGY, 2019, 74 : 82 - 82

← 1 2 3 4 5 →